Understanding Sample Size: Statistical Power, Type I/II Errors & Small Studies

In empirical clinical science, sample size (represented as 'n') is the bedrock of statistical inference [1].

Because biological organisms exhibit natural variability in disease progression, immune response, and healing rates, measuring a small handful of individuals cannot distinguish whether an observed recovery resulted from the experimental peptide or from ordinary biological variance. Larger sample sizes dilute random background noise, allowing true pharmacological signals to emerge with mathematical certainty [1].

When designing a scientific trial, researchers must balance two types of potential mathematical errors [2]:

• Type I Error (False Positive, α): Concluding that a peptide is effective when it is actually inactive. Standard clinical methodology sets this threshold at α = 0.05 (a 5% tolerance for false discovery).
• Type II Error (False Negative, β): Failing to detect a real, beneficial treatment effect because the study enrolled too few subjects.

Statistical Power (1 - β) is the probability that a trial will detect a statistically significant difference of a specified magnitude. Trials are commonly designed for at least 80% power, using pre-trial sample size calculations based on the expected effect size and variability. Yet a survey of 383 randomized trials published in JAMA, Lancet, and NEJM between 1975 and 1990 found that, among the negative two-group trials analysed, only 16% and 36% had 80% power to detect a 25% or 50% relative difference, respectively, and only 32% of negative trials reported a sample size calculation [2].

Underpowered research is plagued by an epistemological trap known as the 'Winner's Curse' [3].

When a study has low power (e.g., 20% to 30%, typical of studies with n = 10 to 30), any finding that manages to cross the p < 0.05 threshold is almost guaranteed to be an extreme statistical outlier. As John Ioannidis demonstrated, the smaller the sample size across a scientific field, the less likely the published research findings are to be true. When these small pilot trials are subsequently replicated in large Phase 3 cohorts (n = 1,000+), the dramatic effect size almost invariably shrinks or disappears completely [3].

In research literature, small studies (n = 10 to 30) are frequently labeled as 'Pilot' or 'Feasibility' trials [4].

The methodological purpose of a pilot study is logistical: testing whether patients can tolerate injections, verifying drug reconstitution procedures, and assessing recruitment rates. Pilot trials are fundamentally unpowered to assess clinical efficacy. Citing a 15-patient pilot study as 'definitive medical proof' that an experimental peptide heals injuries represents a fundamental misunderstanding of clinical trial design [4].

When reviewing evidence for any peptide claim, calibrate your confidence based on the total enrollment scale [1]:

• n < 20: Case series or exploratory pilot; purely hypothesis-generating. High risk of false discovery.
• n = 50 to 200: Phase 2 dose-ranging; provides preliminary signal of efficacy but wide confidence intervals.
• n = 1,000 to 10,000+: Definitive Phase 3 registrational trial; high statistical power to confirm efficacy and characterize common adverse event rates.